NYSE American - Delayed Quote • USD
Matinas BioPharma Holdings, Inc. (MTNB)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:26 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,096.0000
1,096.0000
3,188.0000
33.0000
158.3330
Operating Expense
24,862.0000
24,862.0000
27,778.0000
24,768.0000
24,364.8850
Operating Income
-23,766.0000
-23,766.0000
-24,590.0000
-24,735.0000
-24,206.5520
Other Income Expense
824.0000
824.0000
3,593.0000
1,452.0000
1,759.7140
Pretax Income
-22,942.0000
-22,942.0000
-20,997.0000
-23,283.0000
-22,446.8380
Net Income Common Stockholders
-22,942.0000
-22,942.0000
-20,997.0000
-23,679.0000
-23,240.2800
Diluted NI Available to Com Stockholders
-22,942.0000
-22,942.0000
-20,997.0000
-23,679.0000
-23,240.2800
Basic EPS
-0.11
--
-0.10
-0.11
-0.12
Diluted EPS
-0.11
--
-0.10
-0.11
-0.12
Basic Average Shares
217,264.5260
--
216,811.4390
210,178.3320
196,894.6280
Diluted Average Shares
217,264.5260
--
216,811.4390
210,178.3320
196,894.6280
Total Operating Income as Reported
-23,766.0000
-23,766.0000
-24,590.0000
-24,735.0000
-24,206.5520
Total Expenses
24,862.0000
24,862.0000
27,778.0000
24,768.0000
24,364.8850
Net Income from Continuing & Discontinued Operation
-22,942.0000
-22,942.0000
-20,997.0000
-23,283.0000
-22,446.8380
Normalized Income
-23,426.0000
-23,426.0000
-24,488.0000
-24,611.0000
-23,520.1270
EBIT
-23,766.0000
-23,766.0000
-24,590.0000
-24,735.0000
-24,206.5520
EBITDA
-22,825.0000
-22,825.0000
-23,692.0000
-23,954.0000
-23,431.9650
Reconciled Depreciation
941.0000
941.0000
898.0000
781.0000
774.5870
Net Income from Continuing Operation Net Minority Interest
-22,942.0000
-22,942.0000
-20,997.0000
-23,283.0000
-22,446.8380
Total Unusual Items Excluding Goodwill
484.0000
484.0000
3,491.0000
1,328.0000
1,073.2890
Total Unusual Items
484.0000
484.0000
3,491.0000
1,328.0000
1,073.2890
Normalized EBITDA
-23,309.0000
-23,309.0000
-27,183.0000
-25,282.0000
-24,505.2540
12/31/2020 - 7/21/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACST Acasti Pharma Inc.
2.9000
-2.03%
TOVX Theriva Biologics, Inc.
0.4195
+2.33%
DARE Daré Bioscience, Inc.
0.3059
+5.77%
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
EQ Equillium, Inc.
1.7100
-5.52%
PXMD PaxMedica, Inc.
0.7398
+5.06%
RNAC Cartesian Therapeutics, Inc.
21.03
+0.62%
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%